Varenicline (Champix)
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Additional, Effective Methods to Stop Smoking
Conditions
Additional, Effective Methods to Stop Smoking
Trial Timeline
Jan 1, 2008 → Nov 1, 2011
NCT ID
NCT00832806About Varenicline (Champix)
Varenicline (Champix) is a phase 1 stage product being developed by Pfizer for Additional, Effective Methods to Stop Smoking. The current trial status is completed. This product is registered under clinical trial identifier NCT00832806. Target conditions include Additional, Effective Methods to Stop Smoking.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00832806 | Phase 1 | Completed |